Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer
Clinical trial NCT01669252 · COMPLETED
Trial details
- NCT number
- NCT01669252
- Sponsor
- SOLTI Breast Cancer Research Group
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-08-01
- Primary completion
- 2015-06-01
- Enrollment
- 163
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.